Prognostic scoring systems for patients with refractory/relapsed AML: European Prognostic Index score
| Factor . | Points . |
|---|---|
| CR1 duration | |
| ≥18 mo | 0 |
| 7-18 mo | 3 |
| ≤6 months | 5 |
| Cytogenetics at diagnosis | |
| t(16;16) or inv16 | 0 |
| t(8;21) | 3 |
| Other | 5 |
| Age at relapse | |
| ≤35 y | 0 |
| 36-45 y | 1 |
| >45 y | 2 |
| SCT before first relapse | |
| No | 0 |
| Yes | 2 |
| Factor . | Points . |
|---|---|
| CR1 duration | |
| ≥18 mo | 0 |
| 7-18 mo | 3 |
| ≤6 months | 5 |
| Cytogenetics at diagnosis | |
| t(16;16) or inv16 | 0 |
| t(8;21) | 3 |
| Other | 5 |
| Age at relapse | |
| ≤35 y | 0 |
| 36-45 y | 1 |
| >45 y | 2 |
| SCT before first relapse | |
| No | 0 |
| Yes | 2 |
For information on the EPI score, see Breems et al.34 Prognostic groups: favorable (1-6 points; OS of 70% at 1 y and 46% at 5 y); intermediate (7-9 points; OS of 49% at 1 y and 18% at 5 y); poor (10-14 points; OS of 16% at 1 y and 4% at 5 y).
SCT, stem cell transplantation.